Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
US-2024336697-A1 · Oct 10, 2024 · US
Synthesis and identification of novel RSK-specific inhibitors
US9040673B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9040673-B2 |
| Application number | US-201013390389-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 13, 2010 |
| Priority date | Aug 14, 2009 |
| Publication date | May 26, 2015 |
| Grant date | May 26, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A composition comprising an SL0101 [kaempferol 3-O-(3″,4″-di-O-acetyl-α-L-rhamnopyranoside)] derivative compound that has enhanced ability to inhibit RSK activity, relative to the parent compound is provided. The compounds have utility for treating any disease or conditions characterized or associated with excess or undesirable RSK activity. For example the RSK inhibitors of the present invention can be used to reduce the proliferation of neoplastic cells or for inhibiting the establishment or maintenance of an intracellular pathogenic infection by pathogens whose pathogenicity derives in part from the pathogen's ability to impede endosomal/phagosomal maturation in the host cell.
First claim
Opening claim text (preview).
What is claimed is: 1. A RSK inhibitor represented by the general structure of Formula III wherein R 1 , R 3 and R 7 are each hydroxyl; R 5 , R 6 , R 8 and R 9 are each hydrogen; R 10 , R 11 and R 20 are independently selected from the group consisting of hydroxyl, —NHOCOR 14 , —OCOR 14 , —COR 14 and C 1 -C 4 alkoxy; X is O or CH 2 ; and…
Assignees
Inventors
Classifications
Chemistry & Metallurgy · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9040673B2 cover?
- A composition comprising an SL0101 [kaempferol 3-O-(3″,4″-di-O-acetyl-α-L-rhamnopyranoside)] derivative compound that has enhanced ability to inhibit RSK activity, relative to the parent compound is provided. The compounds have utility for treating any disease or conditions characterized or associated with excess or undesirable RSK activity. For example the RSK inhibitors of the present inventi…
- Who is the assignee on this patent?
- Hecht Sidney M, Lannigan-Macara Deborah A, Smith Jeffrey Allan, and 3 more
- What technology area does this patent fall under?
- Primary CPC classification A61K31/535. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue May 26 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).